Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, SRF388) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced, or...

MLA

Li, Daneng, et al. “Results from a Phase 2 Study of Triplet Blockade of the IL-27, PD-(L)1, and VEGF Pathways with Casdozokitug (Casdozo, SRF388) in Combination with Atezolizumab (Atezo) and Bevacizumab (Bev) in Patients with Unresectable, Locally Advanced, Or..” Journal of Clinical Oncology, vol. 42, Jan. 2024, p. 470. EBSCOhost, https://doi.org/10.1200/JCO.2024.42.3_suppl.470.

APA

Li, D., Rau, K.-M., Yu, M.-L., Chon, H. J., Lai, H.-C., Pelster, M., Roberts, S. K., Crysler, O. V., Vaccaro, G. M., Womack, M. S., Kim, J. W., Yang, J.-M., Kim, H.-D., Hill, J., Reichert, V. L., Masia, R., Harshman, L. C., Hsu, C.-H., & Kang, Y.-K. (2024). Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, SRF388) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced, or.. Journal of Clinical Oncology, 42, 470. https://doi.org/10.1200/JCO.2024.42.3_suppl.470

Chicago

Li, Daneng, Kun-Ming Rau, Ming-Lung Yu, Hong Jae Chon, Hsueh-Chou Lai, Meredith Pelster, Stuart K. Roberts, et al. 2024. “Results from a Phase 2 Study of Triplet Blockade of the IL-27, PD-(L)1, and VEGF Pathways with Casdozokitug (Casdozo, SRF388) in Combination with Atezolizumab (Atezo) and Bevacizumab (Bev) in Patients with Unresectable, Locally Advanced, Or..” Journal of Clinical Oncology 42 (January): 470. doi:10.1200/JCO.2024.42.3_suppl.470.